BRIEF published on 08/08/2024 at 07:35, 3 months 13 days ago Evotec Advances Neuroscience Partnership with Bristol Myers Squibb Partnership Research Neuroscience Evotec Bristol Myers Squibb
PRESS RELEASE published on 08/08/2024 at 07:30, 3 months 13 days ago Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb Evotec SE announces progress in strategic neuroscience partnership with Bristol Myers Squibb, receiving US$ 25 million payment for further research on neurodegenerative diseases Evotec SE Research Neurodegenerative Diseases Bristol Myers Squibb Neuroscience Partnership
BRIEF published on 08/07/2024 at 13:05, 3 months 14 days ago Evotec SE to Announce First Half-Year 2024 Results on 14 August 2024 Financial Results Conference Call Evotec SE Webcast First Half-year 2024
PRESS RELEASE published on 08/07/2024 at 13:00, 3 months 14 days ago Evotec SE reports first half-year 2024 results on 14 August 2024 Evotec SE to report first half-year 2024 results on 14 August 2024. Conference call scheduled to discuss financial performance and updates. Webcast available on www.evotec.com/en/investor-relations/financial-publications Conference Call Financial Performance Evotec SE Webcast First Half-year Results
BRIEF published on 08/06/2024 at 21:12, 3 months 14 days ago Evotec Provides Updated Fiscal Guidance for 2024 Adjusted EBITDA Revenue Forecast Sustainable Growth 2024 Guidance Evotec
BRIEF published on 08/06/2024 at 21:09, 3 months 14 days ago Evotec SE Updates Financial Guidance for 2024 Adjusted EBITDA Revenue Forecast Financial Guidance Evotec SE R&D Expenditure
PRESS RELEASE published on 08/06/2024 at 21:07, 3 months 14 days ago Evotec provides guidance update Evotec SE refines guidance for fiscal year 2024, expecting moderate revenue growth, reduced R&D expenditures, and adjusted EBITDA; aims for sustainable profitable growth amid market challenges Adjusted EBITDA Revenue Growth Evotec SE Guidance Update R&D Expenditures
PRESS RELEASE published on 08/06/2024 at 21:04, 3 months 14 days ago EQS-Adhoc: Evotec SE provides guidance update Evotec SE refines guidance for fiscal year 2024, expecting revenue and EBITDA adjustments due to slower sales conversion and margin pressures, focusing on sustainable growth EBITDA Revenue Evotec SE Sustainable Growth Guidance Update
BRIEF published on 07/10/2024 at 07:35, 4 months 11 days ago Evotec and Pfizer Collaborate to Advance Drug Discovery in France Drug Discovery Metabolic Diseases Evotec Pfizer Infectious Diseases
PRESS RELEASE published on 07/10/2024 at 07:30, 4 months 11 days ago Evotec and Pfizer collaborate to advance drug discovery in France Evotec SE collaborates with Pfizer to focus on early discovery research for metabolic and infectious diseases in France. The multi-year agreement includes research support and potential milestones Drug Discovery Evotec SE France Pfizer Metabolic And Infectious Diseases
Published on 11/21/2024 at 17:35, 15 minutes ago 1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 20 minutes ago SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 1 hour 20 minutes ago The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 1 hour 49 minutes ago Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 1 hour 50 minutes ago Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 15:41, 2 hours 8 minutes ago Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 2 hours 26 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 2 hours 27 minutes ago Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 2 hours 28 minutes ago Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 06:58, 10 hours 52 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 22 hours 30 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 10 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
